3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
2
Thoracic
1
Head & Neck
1
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neoplasms by Site
1
Neoplasms
1
Lung Neoplasms
1
Lung Diseases
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
Pemetrexed
7
Carboplatin
7
Cisplatin
5
pembrolizumab
4
durvalumab
4
osimertinib
3
Paclitaxel
3
selpercatinib
2
pralsetinib
2
cobimetinib
2
Radiosurgery
2
Erlotinib Hydrochloride
2
130-nm albumin-bound paclitaxel
2
trametinib
1
taletrectinib
1
sotorasib
1
repotrectinib
1
patritumab
1
napabucasin
1
glutathione pegylated liposomal doxorubicin
1
ficlatuzumab
1
exemestane
1
enzalutamide
1
entinostat
1
dabrafenib
1
ceralasertib
1
cemiplimab
1
camrelizumab
1
atezolizumab
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
exemestane
×
Thoracic
×
Clear all
NCT01594398
2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1
Completed
14 enrolled